Screener
Design Therapeutics, Inc. DSGN Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 12,388 | 13,700 |
| Commitments and contingencies (See Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 62,441,429 and 60,398,051 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 6 | 6 |
| Additional paid-in capital | 532,958 | 509,100 |
| Accumulated deficit | (314,642) | (297,006) |
| Accumulated other comprehensive (loss) income | (268) | 403 |
| Total stockholders’ equity | 218,054 | 212,503 |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s common stock?
- Design Therapeutics, Inc. (DSGN) reported common stock of $6K in Q1 2026.
- How has Design Therapeutics, Inc.'s common stock changed year-over-year?
- Design Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from $6K to $6K.
- What is the long-term trend for Design Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s common stock has grown at a 43.1% compound annual growth rate (CAGR), from $1K to $6K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Design Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude